Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with <i>EGFR</i>-mutated non-small-cell lung cancer (NSCLC). First-generation EGFR-TKIs (e.g., gefitinib and erlotinib) or second-generation EGFR-TKIs (e.g., a...

Full description

Bibliographic Details
Main Authors: Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura
Format: Article
Language:English
Published: MDPI AG 2018-11-01
Series:Cells
Subjects:
acquired resistance
T790M
C797S
alternative pathway
transformation
primary resistance
Online Access:https://www.mdpi.com/2073-4409/7/11/212

Internet

https://www.mdpi.com/2073-4409/7/11/212

Similar Items